Literature DB >> 19464473

Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure.

Young Keun On1, Eun-Seok Jeon, Sang Yeub Lee, Dae-Hee Shin, Jin-Oh Choi, Jidong Sung, June Soo Kim, Kiick Sung, Pyowon Park.   

Abstract

OBJECTIVES: The Cox maze procedure was developed as a surgical treatment for atrial fibrillation. However, atrial fibrillation recurs in some patients, and atrial remodeling in the form of fibrosis can lead to perpetuation of atrial fibrillation. To identify the predictor of the persistence of atrial fibrillation after the maze procedure using cryoablation, we evaluated the preoperative plasma transforming growth factor beta1. We also examined the correlations between plasma transforming growth factor beta1 levels and the degree of atrial fibrosis.
METHODS: Preoperative plasma transforming growth factor beta1 levels were measured in 86 consecutive patients (age, 54 +/- 12 years) who underwent both the open heart operation for valvular heart disease and the surgical maze procedure with cryoablation for persistent atrial fibrillation. We measured the degree of fibrosis from the tissue of the left atrium.
RESULTS: At 1 year's follow-up, 10 of 86 patients had persistent atrial fibrillation. Patients with persistent atrial fibrillation had higher preoperative plasma transforming growth factor beta1 levels than the patients with sinus rhythm (0.44 +/- 0.29 vs 0.32 +/- 0.15 ng/mL, P = .03). Patients with persistent atrial fibrillation had higher mRNA expressions of collagen III and lower mRNA expressions of atrial natriuretic peptide than those with sinus rhythm, and the plasma transforming growth factor beta1 levels correlated with the degree of fibrosis in the left atrium (r = 0.497, P = .022). Multiple logistic regression analysis revealed that plasma transforming growth factor beta1 levels were independently associated with the postoperative persistence of atrial fibrillation at 1 year's follow-up.
CONCLUSIONS: Preoperative plasma transforming growth factor beta1 levels could be used to predict the persistence of atrial fibrillation at 1 year's follow-up after the surgical maze procedure by using cryoablation. Preoperative plasma transforming growth factor beta1 levels were correlated with the degree of fibrosis in the left atria of patients with mitral valvular heart disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464473     DOI: 10.1016/j.jtcvs.2008.10.022

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  13 in total

1.  Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS).

Authors:  Michael A Rosenberg; Marlena Maziarz; Alex Y Tan; Nicole L Glazer; Susan J Zieman; Jorge R Kizer; Joachim H Ix; Luc Djousse; David S Siscovick; Susan R Heckbert; Kenneth J Mukamal
Journal:  Am Heart J       Date:  2014-02-26       Impact factor: 4.749

2.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

Review 3.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

4.  Does the expression of transforming growth factor β-1: affect the outcome of the radiofrequency modified maze procedure in patients with rheumatic atrial fibrillation?

Authors:  Wei Wang; Lei Liu; Yuan Li; Sheng-Shou Hu; Yun-Hu Song; Xin Wang
Journal:  Tex Heart Inst J       Date:  2012

Review 5.  Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation.

Authors:  Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir
Journal:  Cardiol Rev       Date:  2016 Mar-Apr       Impact factor: 2.644

6.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

7.  Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study.

Authors:  Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djousse; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Sicovick; Russell P Tracy; Kenneth J Mukamal
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-06-24

8.  Possible involvement of TGF-β/periostin in fibrosis of right atrial appendages in patients with atrial fibrillation.

Authors:  Han Wu; Jun Xie; Guan-Nan Li; Qin-Hua Chen; Ran Li; Xin-Lin Zhang; Li-Na Kang; Biao Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

9.  Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model.

Authors:  Michiro Kiryu; Shinichi Niwano; Hiroe Niwano; Jun Kishihara; Yuya Aoyama; Hidehira Fukaya; Yoshihiko Masaki; Tohru Izumi
Journal:  Europace       Date:  2012-03-27       Impact factor: 5.214

10.  TheTGFB1 functional polymorphism rs1800469 and susceptibility to atrial fibrillation in two Chinese Han populations.

Authors:  Weixing Zheng; Chenghui Yan; Xiaohu Wang; Zhurong Luo; Fengping Chen; Yuhui Yang; Donglin Liu; Xiaobo Gai; Jianping Hou; Mingfang Huang
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.